期刊文献+

吉米沙星治疗泌尿系反复感染的临床疗效观察 被引量:2

Effect and Safety of Gemifloxacin in Treatment of Urinary Tract Infections
下载PDF
导出
摘要 目的:探讨吉米沙星治疗泌尿系反复感染的临床疗效与安全性。方法:103例泌尿系反复感染患者随机分为两组,治疗组52例口服吉米沙星320 mg,qd,对照组51例口服左氧氟沙星200 mg,bid,疗程均为10~14 d。结果:两组患者临床总有效率分别为92.31%和86.27%,两组差异无统计学意义(P>0.05)。细菌清除率分别为86.0%和65.9%,两组比较有显著差异(P<0.05)。且未见严重不良反应。结论:吉米沙星治疗泌尿系反复感染安全、有效、使用方便,是治疗泌尿系反复感染的选择。 Objective : To evaluate the therapeutic effect and safty of gemifloxacin in treatment of urinary tract infections. Method: One hundred and three patients with urinary tract infections were divided randomly into two groups, which 52 cases in therapy group re- ceived Gemifioxacin and 51 cases in control group received Levofloxacin for 14 days. Result: The effective rate of two groups was 92. 31% and 86. 27%, respectively. There was no significant differences between two groups (P 〉 0. 05 ). The rate of eliminating the bacteria was 86.0% ,65.9% ,respectively. There was significant differences between two groups (P 〈 0. 05 ). There was no severe adverse reactions in the two groups. Conclusion: Gemifloxacin is effective and safe in treatment of urinary tract infections, and it will be a new choiee for severe urinary tract infections.
作者 张强
出处 《中国药师》 CAS 2010年第8期1154-1155,共2页 China Pharmacist
关键词 吉米沙星 左氧氟沙星 泌尿系反复感染 Gemifloxacin Levofloxaein Urinary tract infections
  • 相关文献

参考文献7

二级参考文献62

  • 1Lowe MN,Lamb HM.Gemifloxacin[J].Drugs,2000,59(5):1137-1147.
  • 2Cormican MG,Jones RN.Antimicrobial activity and spectrum of LB20304,a novel fluoronaphthyridone[J].Antimicrob Agents Chemother,1997,41(1):204-211.
  • 3Goldstein EJC,Citron DM,Warren Y,et al.In vitro activity of gemifloxacin(sb 265805)against anerobes[J].Antimicrob Agents Chemother,1999,43(9):2231-2235.
  • 4Allen A,Bygate E,Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers[J].Antimicrob Agents Chemother,2001,45(2):540-545.
  • 5Gee T,Andrews JM,Ashby JP,et al.Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose[J].J Antimicrob Chemother,2001,47(4):431-434.
  • 6Allen Avousden M,Lewis A.Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers[J].Chemotherapy Basel,1999,45(6):496-503.
  • 7File TM,Schlemmer JB.Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia:a randomized,double-blind comparison with trovafloxacin[J].J Antimicro Chemother,2001,48(1):67-74.
  • 8File T,Schlemmer B,Garau J.Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis[J].J Chemother,2000,12(4):314-325.
  • 9Lode H,File TM Jr,Mandell L,et al.185 Gemifloxacin Study Group.Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia:a randomized,open-label,multicenter study of clinical efficacy and tolerability[J].Clin Ther,2002,24(11):1915-1936.
  • 10Mandell L. Gemifloxacin: survival of the fittest[J]. J Antimicrob Chemother, 2000, 46(Suppl T1): 33-37

共引文献58

同被引文献42

  • 1陈雪华,何礼贤.氟喹诺酮类药物的药动学和药效学[J].中华医学信息导报,2004(10):20-20. 被引量:8
  • 2崔俊昌,刘又宁,王睿,梁蓓蓓,郑专杰.氟喹诺酮类药物对临床分离金黄色葡萄球菌的防耐药变异浓度[J].中华医院感染学杂志,2005,15(6):611-614. 被引量:10
  • 3史红耀,黄仲义,黄毅慧,范英,沈麦琪,仇益群.吉米沙星与左氧氟沙星治疗下呼吸道感染的随机对照比较[J].中国新药与临床杂志,2007,26(9):678-680. 被引量:7
  • 4郭庆兰,阚丽娅,刘德梦,等.住院病例抗菌药物应用调查及耐药性分析[G].2004年全国危重病急救医学学术会议论文集,2004:139-140.
  • 5Smith JL, Fratamico PM. Fluoroquinolone resistance in carnpylohacter [J]. J Food Prot, 2010,73(6) :1141 -1152.
  • 6Pallo - Zimmerman LM, Byron JK, Graves TK. Fluoroquinolones : then and now[J]. Compend Contin Edue Vet, 2010,32(7) :El -9.
  • 7Yamaguchi H, Kawai H, Matsumoto T, et al. Post - marketing surveil- lance of the safety of levofloxacin in Japan [ J ]. Chemotherapy, 2007,53 (2) :85 - 103.
  • 8Fish DN,Chow AT.The clinical pharmacikinetics of levofloxacin[J].Clin Pharmacokinet,1997,32(2):101-119.
  • 9Zhanel GG,Ennis K,Vercaigne L,et al.A critical review of the fluoroquinolones:focus on respiratory tract infections[J].Drugs,2002,62(1):13-59.
  • 10Crandon JL,Kuti JL,Jones RN,et al.Comparison of2002-2006 OPTAMA programs for US hospitals:focus on gram-negative resistance[J].Ann Pharmacother,2009,43(2):220-227.

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部